Agusti A, Torres F, Faner R. Early treatment with inhaled budesonide to prevent clinical deterioration in patients with COVID-19. Lancet Respir Med 2021; published online April 9. https://doi.org/10.1016/S2213-2600(21)00171-5—In this Comment, the dose of budesonide should have been 400 μg per actuation, to a total dose (two puffs to be taken twice per day) of 1600 μg. This correction has been made to the online version as of April 14, 2021, and the printed version is correct.
. 2021 Apr 14;9(6):e55. doi: 10.1016/S2213-2600(21)00186-7
Correction to Lancet Respir Med 2021; published online April 9. https://doi. org/10.1016/S2213-2600(21)00171-5
Issue date 2021 Jun.
© 2021 Elsevier Ltd. All rights reserved.
Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
PMCID: PMC8046412 PMID: 33864734
This corrects the article "Early treatment with inhaled budesonide to prevent clinical deterioration in patients with COVID-19" on page 682.